EN
Srpski (SR)
Deutsch (DE)
STADA Group business results in Q2 and the first six months of 2017
03. August 2017.
STADA shows good operational development in first six months of 2017

  • Significant increase in Group sales (+10 percent), EBITDA (+10 percent) and net income (+10 percent)
  • Strong growth and significant margin improvement in Generics – sales (+8 percent), EBITDA (+17 percent), EBITDA margin (+180 basis points)
  • Significant growth in Branded Products – sales (+15 percent), EBITDA (+16 percent)
  • Improvement in net debt to adjusted EBITDA ratio to 2.3
MAIN RX PRODUCTS
Bromazepam
Metformin
Diclofenac
Lorazepam
Bisoprolol
Amoxicillin
Metoprolol
Azithromycin
Enalapril
Propafenone
HEMOFARM OVER-THE-COUNTER DRUGS
Panlax
Snup
Ibumax
Hepathrombin
Pressing
Mycoseb
HEMOFARM A.D.
About Us
Do business with us
STADA Group
+381 13 803 100
svakodobro@hemofarm.com

Compliance Reporting Portal

Terms of conditions
Privacy Notice
Personal Data Processing Notification
Copyright© Hemofarm 2025